Saving Our Troops: An Efficacy Model for Platelet Replacement Products

//Saving Our Troops: An Efficacy Model for Platelet Replacement Products

Saving Our Troops: An Efficacy Model for Platelet Replacement Products

The best way to support our troops is to help them come home healthy. Over 52,280 United States service members were wounded in action during the conflicts in Iraq and Afghanistan (Congressional Research Service

[1]).  Many of these injuries were associated with blood loss. To prevent excessive blood loss, researchers are developing novel platelet replacement products.

blood-loss-over-timeThere are several published in vivo efficacy models for platelet replacement products including radiation induction and chemical induction. MPI Research chose to use a chemical induction model over radiation induction as it had fewer reported side-effects. Historically, blood loss has been assessed using bleeding and clotting time which are highly variable, subjective, and technician dependent. Our efficacy model provides rapid and reliable results that are highly quantitative.

The MPI Research thrombocytopenia model in rabbits is based on historical publications[2]. The platelets in the rabbit are depleted by busulfan induction. This is a historical model with relevance to assessing the efficacy of modern platelet substitutes and platelet-derived products. Previous work demonstrated a reduction in platelet levels after repeated subcutaneous injections of busulfan with minimal decrease in hemoglobin and leukocytes. Once platelet levels reach below threshold levels, vehicle control or platelet replacement products can be administered.

Efficacy is quantitatively measured as a percent of total blood loss. Red blood cells in whole blood are labeled with 51Cr. As blood loss occurs into a saline bath, the blood/saline mixture is sampled and analyzed for radioactivity. This is compared to the amount of radioactivity in the blood at steady-state. The method is sensitive enough to detect loss of a single drop of blood.

Platelet replacement products help many people; from troops suffering from combat injuries to patients undergoing surgery and families in car accidents. MPI Research is proud to be part of helping save lives by providing a model for testing the efficacy of platelet replacement products.

[1][2] Kuter, D.J., and R.D. Rosenberg. “The Reciprocal Relationship of Thrombopoietin (c-Mpl Ligand) to Changes in the Platelet Mass During Busulfan-Induced Thrombocytopenia in the Rabbit.” Blood. 1995 May 15;85(10):2720-30.
By |2017-07-04T10:27:03+00:00October 1st, 2015|Blog|Comments Off on Saving Our Troops: An Efficacy Model for Platelet Replacement Products

About the Author:

MPI Research, with global headquarters in Mattawan, Mich., provides safety evaluation, discovery, bioanalytical and analytical services to the biopharmaceutical, medical device, animal health, and chemical industries. The company offers comprehensive imaging solutions including preclinical imaging, radiochemistry, and data analysis. Scientific knowledge and experience, responsiveness, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world.